home

Immunomic Therapeutics' next-generation immunotherapy vaccine platform,
UNITE (Universal Intracellular Targeted Expression),
is used to develop therapeutic vaccines for cancer,
allergies and animal health by enhancing the function of cytotoxic T cells.

Mechanism of activation of immune system activation

UNITE platform is a powerful next-generation vaccine platform technology that targets specific antigens to lysosomes to enhance antigen presentation ability and enhances cytotoxic T cell function.
The anticancer drug under development using the UNITE platform technology from Immunomic Therapeutics is an immune anticancer drug that enhances the immune system of cancer patients by mounting cancer-specific antigens on immune cells with high efficiency.

Indication

Glioblastoma

Glioblastoma is a primary tumor originating from the brain-spinal tissue or the membrane that surrounds it. It is a tumor originated from the glioma cells (Neuroglia Cells) that are normally abundant in brain tissue.

Glioblastoma is grade 4 in astrocytoma and is the most malignant among astrocytoma and histologically, necrosis is added to anaplastic astrocytoma.
This tumor is the most common primary brain tumor, accounting for 1/2 of glioma and 15% of pediatric glioma, and rarely occurs in the cerebellum.
The 2000 WHO taxonomy includes glioblastomas, including giant cell glioblastoma and gliosarcoma.

* source: National Information Cancer Center

Pipeline
Program Therapeutic Area Indication Target / Modality Stage of Development Lead Developing Entity
Discovery Pre-clinical Phase 1 Phase 2
ITI-1000 Oncology GBM DC-based pp65 CMV
       
Immunomic
ITI-1001 Oncology GBM pDNA pp65.gB, IE1:CMV
       
Immunomic
ITI-2000 Oncology HPV+ Tumors HPV E6/E7
       
Immunomic
ITI-4000 Oncology NPC / Gastric Epstein-Barr Virus
       
Immunomic
ITI-6000 Oncology HCC HBV ag + Others
       
Immunomic
ITI-7000 Oncology Bladder HERS+NY=ESO-1
       
Immunomic
ITI-3000 Oncology Markel Cell Carcinoma Polyoma pDNA
       
Hutch/UW
ITI-5000 Oncology Neoantigen vaccination PCV pDNA
       
Eplvax Oncology
ITI-AB1 Oncology (biologic - MAB) Checkpoint Inhibitor HVEM
       
Immunomic
ASP-JRCv2.0 Allezy Japanese Ped Cedar pDNA
       
Astellas
ASP-0892 Allezy Peanut pDNA
       
Astellas
ASP-2390 Allezy HDM + other Allergens pDNA
       
Astellas
Animal Health All All pDNA
       
Zenoaq
clinical trial status
01.
1st line treatment of Glioblastoma

Phase II clinical trials are in progress in the US for the 1st line glioblastoma treatment with ITI-1---(pp65-LAMP DC) therapy